Dr Ritchie is Lead Clinician for Alcohol and Drug Services in Glasgow. She has been a member of the Royal College of General Practitioners since 2001 and worked as a GP in areas of deprivation in Glasgow before moving to work in specialist drug and alcohol services. Her clinical work includes heroin assisted treatment and benzodiazepine harm reduction prescribing. She currently chairs the board’s Medication Assisted Treatment group. Research interests include innovative integration of blood borne virus and drug treatment service delivery, interventions for novel benzodiazepine use and exploring all-cause mortality in drug treatment services.
Service evaluation of implementation of MAT Standards 1 and 2 in Glasgow Alcohol and Drug Recovery Services
Aims: Service evaluation of implementation of MAT Standards 1 and 2 in Glasgow Alcohol and Drug Recovery Services (GADRS)
Design: Treatment Waiting Times data for May 2020, January 2021 and March 2021 was obtained for ADRS teams in Glasgow for people using opiates and used as basis for audit of electronic records.
Setting: GADRS community teams and Homeless Addiction Team
Participants: Information relating to 178 people who reported using opiates at referral was analysed
Measurements: Patient electronic records were audited for date opioid substitution treatment (OST) was started and type of OST chosen.
Findings and conclusions: In May 2020, 75% of 65 referrals were started on OST, 27% on the same day, 47% by day 3. A quality improvement (QI) approach led to development of a Standard Operating Procedure (SOP) to capture operational changes required to improve same day starts. However in January 2021 re-audit there were no same day starts although 52% were started on OST by day 3. This prompted a focus on implementing the SOP and in the most recent audit March 2021, 77% of 65 referrals were started on OST, 32% same day, a further 26% next day and a total of 70% within 3 days. These audit cycles demonstrate improvement in delivering same day OST prescribing in Glasgow. QI learning and OST choice (methadone, buprenorphine tablets or buprenorphine injection) will be described in detail in the poster presentation.